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Fig 1. Epidermolysis bullosa pruriginosa. A, Purple polygonal flat-topped papules coalescing
into large, linear plaques. Bullae occurred on the top of several of these plaques. B, Area shown
in A 6 months after treatment with residual postinflammatory hyperpigmentation and scarring.
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Open access under CC BY-NC-ND license.Orofacial granulomatosis successfully treated
with mycophenolate mofetil
To the Editor: Orofacial granulomatosis (OFG) is a
chronic, relapsing, potentially disfiguring inflamma-
tory disorder of unknown etiology.1 It is character-
ized by persistent enlargement of the orofacial
tissues and noncaseating granulomatous inflamma-
tion on tissue biopsy in the absence of diagnosable
Crohn disease or sarcoidosis.1-3 It is thought that
OFG represents a spectrum of disease ranging from
localized granulomatous inflammation of the lips
(cheilitis granulomatosa, Miescher cheilitis) to
persistent lip or facial swelling with mucosal ulcer-
ation, recurrent facial paralysis, and lingual fissuring
(Melkersson-Rosenthal syndrome).2,3 Due to its
unknown etiology and unpredictable clinical
course, no definitive pharmacologic therapy is yet
available.1,2 We present a case of OFG successfully
treated with mycophenolate mofetil (MMF), sug-
gesting this treatment may be of benefit in these
patients.
A 59-year-old Caucasian woman with a history of
systemic lupus erythematosus, hepatitis C, and
recurrent herpes labialis presented with a 4-month
history of rash and swelling of her upper lip. The
lesion started as a ‘‘cold sore’’ with occasional
burning and mild pruritus. She was treated with
oral steroids and amoxicillin by her primary care
physician with temporary relief and was referred for
further evaluation by a dermatologist. Her condition
was persistent with erythema, mild scaling, and
diffuse swelling of the upper lip extending to the
right oral commissure and lower lip. No other oral
mucosal or lingual lesions were noted and she
Fig 1. Orofacial granulomatosis. Biopsy specimen of the
upper lip at initial presentation showed a dermal lympho-
plasmacytic infiltrate with focal noncaseating granuloma
formation. (Hematoxylin-eosin stain; original magnifica-
tion: 350.)
Fig 2. Orofacial granulomatosis. A, Initial presentation
with erythema and swelling of the upper lip, extending to
the right oral commissure and lower lip. B, Complete
resolution of erythema, swelling, and induration after 6
months of mycophenolate mofetil monotherapy (1000
mg/day). Only a small soft papule remains on the right
lower cutaneous lip.
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testinal symptoms.
A biopsy of her upper lip revealed chronic dermal
inflammation with focal granuloma formation
(Fig 1). Gram, Fite, and periodic acideSchiff stains
were negative. Complete blood count, serum
angiotensin-converting enzyme, C-reactive protein,
tuberculin skin test, chest radiographs, funduscopic
examination, and prior colonoscopy were all
unremarkable. Based on these findings, OFG was
diagnosed.
High-potency topical steroids, valacyclovir, and
doxycycline yielded no improvement. Systemic ste-
roids were discussed as a treatment option but were
contraindicated due to history of avascular necrosis
of the hip, and she refused intralesional steroid
injections. She was started on MMF 500 mg twice
daily with significant improvement after 1 month and
near complete return to baseline orofacial structural
anatomy after 6 months of therapy (Fig 2). At 1 year
of MMF monotherapy, she continues to be disease-
free with no clinical or laboratory adverse effects of
treatment.
MMF is a potent immunosuppressant widely
described in the dermatology literature for its
attractive safety profile and effectiveness in a
variety of inflammatory skin conditions.4 Two
patients with OFG treated with MMF in combina-
tion with topical therapy (corticosteroids and/ortacrolimus) have been reported, although with
unclear protocols and outcomes.3 A search of
PubMed and Google Scholar using the terms
‘‘mycophenolate mofetil’’ and ‘‘orofacial granulo-
matosis,’’ ‘‘cheilitis granulomatosa,’’ ‘‘Miescher chei-
litis,’’ or ‘‘Melkersson Rosenthal syndrome’’ showed
no previous reports of MMF used as a single-
therapy agent in the successful treatment of OFG.
MMF may be a beneficial treatment option for these
patients, particularly in those who cannot tolerate
systemic or intralesional corticosteroid therapy.
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testosterone-induced erythrocytosis
To the Editor: A 59-year-old healthy man presented
for evaluation of new-onset aquagenic pruritus. He
started testosterone replacement therapy (200 mg
daily) 7 months before presentation for low
testosterone level of unknown cause; testicular
biopsy at that time revealed normal findings. Four
months after beginning testosterone replacement, he
noticed generalized intense burning and pruritus,
specifically during and after showering, without
evidence of rash. Empiric use of emollients and
antifungal cream did not alleviate the pruritus. He
could not tolerate antihistamines because of drows-
iness. On evaluation, his full-body skin examination
revealed normal findings. This history and examina-
tion are consistent with aquagenic pruritus, which
typically presents without cutaneous signs.1 Because
aquagenic pruritus is most often associated with
polycythemia vera (PCV),2 hematologic studies wereFig 1. Aquagenic pruritus associated with testoste
hematocrit level, and testosterone dosage.performed, revealing an elevated hematocrit of
51.2%, notably higher than his normal baseline of
46.5%. The remainder of his complete blood cell
count and differential, renal and liver function tests,
antinuclear antibody, and thyroid studies were
normal.
Because the aquagenic pruritus tightly coincided
with the initiation of his testosterone replacement
therapy, the patient’s testosterone dose was tapered
to 50%, which resulted in significant improvement in
his symptoms; his hematocrit also normalized to
baseline levels (Fig 1). Given that his erythrocytosis
and his symptoms were improving, the patient
was recommended to continue routine monitoring
of his hematocrit levels and did not undergo
further diagnostic evaluation for hematologic
malignancy.
Although most patients with aquagenic pruritus
do not have underlying disease, when associated
with systemic conditions, PCV is diagnosed in
approximately 30% of cases of aquagenic pruritus.3,4
Aquagenic pruritus is reported by approximately 5%
to 69% of patients with PCV and may precede the
diagnosis of PCV by many years.3,4 Aquagenic pru-
ritus may also occur in the setting of myelofibrosis,
malignancy, medications (bupropion, antimalarials),
and lactose intolerance.4 However, little is known
about the mechanism or pathophysiology of
aquagenic pruritus. One study looking at skin
biopsy specimens taken from patients with PCV
and aquagenic pruritus demonstrated increased
skin mast cells, mononuclear cells, and eosinophils.3rone-induced erythrocytosis: clinical course,
